Physician profile
Adonis Imam
NPI 1285096297
$923.37
in general payments reported to CMS, 2019-2025
10 companies · $53.17 in 2025
The $53.17 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $286 · 2021: $92.93 · 2022: $92.56 · 2023: $116 · 2024: $136 · 2025: $53.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $410.02 | 2019-2021 | |
| Abbvie INC. | $165.62 | 2022-2024 | |
| Pfizer INC. | $116.91 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $73.50 | 2020 | |
| Novartis Pharmaceuticals Corporation | $59.93 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $30.69 | 2021-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.66 | 2025 | Xifaxan |
| Lexicon Pharmaceuticals, INC. | $16.42 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $14.15 | 2025 | Eliquis |
| Astrazeneca Pharmaceuticals Lp | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adonis Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.